Dellora Investments LP and its principal Kevin Pyun filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 3,169,287 shares of Whitehawk Therapeutics, Inc. common stock, representing 5.6% of the class based on a triggering event dated September 30, 2026.

Key Highlights

  • Shares reported: Both Dellora Investments LP and Kevin Pyun each report beneficial ownership of 3,169,287 shares of Whitehawk Therapeutics common stock.
  • Ownership percentage: The 3,169,287 shares represent 5.6% of the class, calculated using 57,009,010 shares outstanding as of August 3, 2026.
  • Voting and dispositive power: All 3,169,287 shares are held with shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as 0.
  • Filer identity: Dellora Investments LP is a Delaware-organized investment adviser registered under the Investment Advisers Act of 1940; Kevin Pyun is identified as its Principal.
  • Beneficial ownership disclaimed: According to the filing, both Dellora Investments LP and Kevin Pyun "expressly disclaim beneficial ownership over any of the securities reported in this statement."
  • Triggering event date: The date of the event requiring this filing is stated as September 30, 2026.

Dellora Investments LP Reports 5.6% Position in Whitehawk Therapeutics as of September 30, 2026

According to the Schedule 13G filed November 16, 2026, Dellora Investments LP, based at 41 W Putnam Avenue, Suite 204, Greenwich, CT 06830, serves as investment adviser to private funds and another client, collectively referred to in the filing as the "Funds." The filing states that Dellora Investments LP "may be deemed to be the beneficial owner of all shares of Common Stock held by the Funds." Kevin Pyun, identified as Principal of Dellora Investments LP, is reported to hold the same 3,169,287 shares in his capacity as the person with the power to exercise investment and voting discretion over those Funds.

The filing calculates the 5.6% ownership figure using 57,009,010 shares of Whitehawk Therapeutics common stock outstanding as of August 3, 2026, as the company represented in a Form 10-Q filed with the SEC on August 6, 2026. Whitehawk Therapeutics, Inc. is headquartered at 2 Headquarters Plaza, East Building, 11th Floor, Morristown, New Jersey 07960, according to the filing. The issuer's common stock carries a par value of $0.0001 per share and is identified by CUSIP number 00032Q104.

Both reporting persons certify in the filing that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing does not include a ticker symbol or exchange designation in its text. Dellora Investments LP is classified in the filing as type "IA, HC" (investment adviser and holding company), while Kevin Pyun is classified as type "IN, HC" (individual and holding company).

What Was Disclosed

Dellora Investments LP and Kevin Pyun filed a Schedule 13G disclosing shared beneficial ownership of 3,169,287 shares of Whitehawk Therapeutics, Inc. common stock, equal to 5.6% of the outstanding class, with the triggering event dated September 30, 2026. Both parties disclaim beneficial ownership of the reported securities.